HK1201752A1 - Alternaria peptides - Google Patents

Alternaria peptides Download PDF

Info

Publication number
HK1201752A1
HK1201752A1 HK15102384.3A HK15102384A HK1201752A1 HK 1201752 A1 HK1201752 A1 HK 1201752A1 HK 15102384 A HK15102384 A HK 15102384A HK 1201752 A1 HK1201752 A1 HK 1201752A1
Authority
HK
Hong Kong
Prior art keywords
amino acid
acid sequence
polypeptide
salt
cell epitope
Prior art date
Application number
HK15102384.3A
Other languages
English (en)
Chinese (zh)
Inventor
Roderick Peter Hafner
Paul Laidler
Pascal Hickey
Mark Larche
Original Assignee
Circassia Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46582267&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1201752(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Circassia Limited filed Critical Circassia Limited
Publication of HK1201752A1 publication Critical patent/HK1201752A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ecology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
HK15102384.3A 2012-06-01 2013-05-30 Alternaria peptides HK1201752A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1209868.7A GB201209868D0 (en) 2012-06-01 2012-06-01 Alternaria peptides
GB1209868.7 2012-06-01
PCT/GB2013/051439 WO2013179043A1 (en) 2012-06-01 2013-05-30 Alternaria peptides

Publications (1)

Publication Number Publication Date
HK1201752A1 true HK1201752A1 (en) 2015-09-11

Family

ID=46582267

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102384.3A HK1201752A1 (en) 2012-06-01 2013-05-30 Alternaria peptides

Country Status (17)

Country Link
US (1) US20150098969A1 (enExample)
EP (1) EP2855515A1 (enExample)
JP (1) JP2015520771A (enExample)
KR (1) KR20150028788A (enExample)
CN (1) CN104507959A (enExample)
AU (1) AU2013269326A1 (enExample)
BR (1) BR112014029856A2 (enExample)
CA (1) CA2875130A1 (enExample)
CL (1) CL2014003290A1 (enExample)
EA (1) EA201492268A1 (enExample)
GB (2) GB201209868D0 (enExample)
HK (1) HK1201752A1 (enExample)
IL (1) IL235840A0 (enExample)
IN (1) IN2014DN10558A (enExample)
MX (1) MX2014014461A (enExample)
SG (1) SG11201407975TA (enExample)
WO (1) WO2013179043A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160130311A1 (en) * 2013-06-05 2016-05-12 Maria R. Diaz-Torres T cell epitopes derived from alt a 1 or alt a 5 for the treatment of alternaria alternata allergy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT400723B (de) * 1993-08-27 1996-03-25 Biomay Prod & Handel Rekombinante alternaria alternata allergene
JP2007176953A (ja) * 1996-03-10 2007-07-12 Meiji Milk Prod Co Ltd アレルギー疾患に対するペプチド免疫療法剤
JP2003116556A (ja) * 2001-10-09 2003-04-22 Nippon Zenyaku Kogyo Kk アレルギー性皮膚炎治療剤
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
ES2402956T3 (es) * 2007-08-15 2013-05-10 Circassia Limited Péptido con formación de dímeros reducida
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
US20130259884A1 (en) * 2010-09-24 2013-10-03 Alergenetica Sl Peptides

Also Published As

Publication number Publication date
IN2014DN10558A (enExample) 2015-08-21
AU2013269326A1 (en) 2014-12-18
KR20150028788A (ko) 2015-03-16
BR112014029856A2 (pt) 2017-07-25
IL235840A0 (en) 2015-01-29
US20150098969A1 (en) 2015-04-09
SG11201407975TA (en) 2015-01-29
CA2875130A1 (en) 2013-12-05
JP2015520771A (ja) 2015-07-23
GB201209868D0 (en) 2012-07-18
EA201492268A1 (ru) 2015-05-29
GB2517871A (en) 2015-03-04
CL2014003290A1 (es) 2015-05-22
EP2855515A1 (en) 2015-04-08
MX2014014461A (es) 2015-02-10
WO2013179043A1 (en) 2013-12-05
CN104507959A (zh) 2015-04-08

Similar Documents

Publication Publication Date Title
HRP20192314T1 (hr) Pripravci faktora viii i postupci pripreme i njihove uporabe
MY171146A (en) Compositions of glp-1 peptides and preparation thereof
NZ621868A (en) Growth hormone polypeptides and methods of making and using same
EP2594582A3 (en) Peptide vaccines with Seq Id No: 110, 111, 387, 112, 394 114, 116, 117 or 121 for cancers expressing tumor-associated antigens
GB201206559D0 (en) Polypeptide
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
JP2013172734A5 (enExample)
EP4276180A3 (en) Clostridium histolyticum enzyme
IN2014DN09963A (enExample)
JP2015510393A5 (enExample)
EA201990885A1 (ru) Композиции, содержащие короткие пептиды, полученные из pedf, и их применение
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
NZ756128A (en) Novel peptides and analogs for use in the treatment of oral mucositis
NZ602693A (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
WO2014037565A3 (en) Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof
WO2013096868A3 (en) Saposin-a derived peptides and uses thereof
JP2010265269A5 (enExample)
HK1201850A1 (en) Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
WO2013021284A3 (en) Anti-il-6 vaccine composition
MX2009007261A (es) Vacuna de peptido foxp3.
NZ703514A (en) Fviii peptides for immune tolerance induction and immunodiagnostics
WO2008113970A3 (en) Peptides
WO2015040609A8 (en) Erk-derived peptides and uses thereof
WO2010103515A3 (en) Compositions and methods for prevention and treatment of neurodegenerative diseases
MX2010005816A (es) Epítopos de péptido de stat3.